Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
- Conditions
- Interventions
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 703
- Registration Number
- NCT04210115
- Locations
- 🇺🇸
Greater Baltimore Medical Center ( Site 0031), Baltimore, Maryland, United States
🇺🇸Allegheny Health Network ( Site 0042), Pittsburgh, Pennsylvania, United States
🇧🇷ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088), Ijui, Rio Grande Do Sul, Brazil
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 94
- Registration Number
- NCT04205968
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Swedish Medical Center-Ballard Campus, Seattle, Washington, United States
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
- Conditions
- Interventions
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 252
- Registration Number
- NCT04166318
- Locations
- 🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 90
- Registration Number
- NCT04164238
- Locations
- 🇨🇳
Department of Medical Onocology, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Anne Noonan
- Target Recruit Count
- 9
- Registration Number
- NCT04164069
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 52
- Registration Number
- NCT04150640
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
- Conditions
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 2079
- Registration Number
- NCT04127019
CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 112
- Registration Number
- NCT04097444
- Locations
- 🇯🇵
Ac Medical Inc., Chuo Ku, Tokyo, Japan
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 455
- Registration Number
- NCT04094688
- Locations
- 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 1287
- Registration Number
- NCT04083599
- Locations
- 🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸Cancer & Blood Specialty Clinic, Los Alamitos, California, United States
🇺🇸Moores Cancer Center at the UC San Diego Health, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.